• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种基于免疫的风险分层系统,用于预测肺肉瘤样癌(PSC)的预后。

An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC).

机构信息

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China.

School of Medicine, Tongji University, Shanghai, China.

出版信息

Oncoimmunology. 2021 Jul 13;10(1):1947665. doi: 10.1080/2162402X.2021.1947665. eCollection 2021.

DOI:10.1080/2162402X.2021.1947665
PMID:34290908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8279095/
Abstract

Pulmonary sarcomatoid carcinoma (PSC) is an uncommon subtype of lung cancer, and immune checkpoint blockade promises in clinical benefit. However, virtually nothing is known about the expression of common immune checkpoints in PSC. Here, we performed immunohistochemistry (IHC) to detect nine immune-related proteins in 97 PSC patients. Based on the univariable Cox regression, random forests were used to establish risk models for OS and DFS. Moreover, we used the GSEA, CIBERSORT, and ImmuCellAI to analyze the enriched pathways and microenvironment. Univariable analysis revealed that CD4 ( = 0.008), programmed cell death protein 1 (PD-1; = 0.003), galectin-9 (Gal-9) on tumor cells (TCs; = 0.021) were independent for DFS, while CD4 ( = 0.020), PD-1 ( = 0.004), Gal-9 ( = 0.033), and HLA on TILs ( = 0.031) were significant for OS. Meanwhile, the expression level of CD8 played a marginable role in DFS ( = 0.061), limited by the number of patients. The combination of Gal-9 on TC with CD4 and PD-1 on TILs demonstrated the most accurate prediction for DFS (AUC: 0.636-0.791, F1-score: 0.635-0.799), and a dramatic improvement to TNM-stage ( < 0.001 for F1-score of 1-y, 3-y, and 5-yDFS). A similar finding was also observed in the predictive ability of CD4 for OS (AUC: 0.602-0.678, F1-score: 0.635-0.679). CD4 was negatively associated with the infiltration of neutrophils ( = 0.015). PDCD1 (coding gene of PD-1) was positively correlated to the number of exhausted T cells (Texs; = 0.020) and induced regulatory T cells (iTregs; = 0.021), and LGALS9 (coding gene of Gal-9) was positively related to the level of dendritic cells (DCs; = 0.021). Further, a higher combinational level of CD4, PDCD1 on TILs, and LAGLS9 on TCs were proved to be infiltrated with more M1-type macrophages ( < 0.05). We confirmed the expression status of nine immune-related proteins and established a TNM-Immune system for OS and DFS in PSC to assist clinical risk-stratification.

摘要

肺肉瘤样癌(PSC)是一种罕见的肺癌亚型,免疫检查点阻断在临床上有获益的前景。然而,实际上对于 PSC 中常见免疫检查点的表达情况知之甚少。在这里,我们对 97 例 PSC 患者进行了免疫组化(IHC)检测,以检测 9 种与免疫相关的蛋白。基于单变量 Cox 回归,随机森林被用于建立 OS 和 DFS 的风险模型。此外,我们使用 GSEA、CIBERSORT 和 ImmuCellAI 来分析富集的通路和微环境。单变量分析显示,CD4(=0.008)、程序性死亡蛋白 1(PD-1;=0.003)、肿瘤细胞(TCs)上的半乳糖凝集素-9(Gal-9;=0.021)是 DFS 的独立预后因素,而 CD4(=0.020)、PD-1(=0.004)、Gal-9(=0.033)和 TILs 上的人类白细胞抗原(HLA;=0.031)是 OS 的显著预后因素。同时,CD8 的表达水平在 DFS 中也起着重要作用(=0.061),但受患者数量的限制。TCs 上的 Gal-9 与 TILs 上的 CD4 和 PD-1 的组合对 DFS 的预测最为准确(AUC:0.636-0.791,F1 得分:0.635-0.799),并极大地改善了 TNM 分期(1 年、3 年和 5 年 DFS 的 F1 得分<0.001)。在 CD4 对 OS 的预测能力中也观察到了类似的发现(AUC:0.602-0.678,F1 得分:0.635-0.679)。CD4 与中性粒细胞浸润呈负相关(=0.015)。PDCD1(PD-1 的编码基因)与耗竭性 T 细胞(Texs;=0.020)和诱导性调节性 T 细胞(iTregs;=0.021)的数量呈正相关,LGALS9(Gal-9 的编码基因)与树突状细胞(DCs;=0.021)的水平呈正相关。进一步研究发现,TILs 上的 CD4 和 PDCD1 以及 TCs 上的 LGALS9 联合水平较高的患者,其 M1 型巨噬细胞浸润更多(<0.05)。我们证实了 9 种免疫相关蛋白的表达状态,并建立了 PSC 用于 OS 和 DFS 的 TNM-免疫系统,以协助临床风险分层。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/1fa71d9a1df9/KONI_A_1947665_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/437be9587fad/KONI_A_1947665_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/d47f463c7b95/KONI_A_1947665_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/ba66767b5a82/KONI_A_1947665_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/c2aad6f6d829/KONI_A_1947665_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/aaf4b1a6f194/KONI_A_1947665_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/159bf3c9ab59/KONI_A_1947665_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/1fa71d9a1df9/KONI_A_1947665_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/437be9587fad/KONI_A_1947665_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/d47f463c7b95/KONI_A_1947665_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/ba66767b5a82/KONI_A_1947665_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/c2aad6f6d829/KONI_A_1947665_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/aaf4b1a6f194/KONI_A_1947665_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/159bf3c9ab59/KONI_A_1947665_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fa0/8279095/1fa71d9a1df9/KONI_A_1947665_F0007_OC.jpg

相似文献

1
An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC).一种基于免疫的风险分层系统,用于预测肺肉瘤样癌(PSC)的预后。
Oncoimmunology. 2021 Jul 13;10(1):1947665. doi: 10.1080/2162402X.2021.1947665. eCollection 2021.
2
Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.基于半乳糖凝集素-9 的免疫风险评分模型有助于预测 I-III 期小细胞肺癌的复发。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001391.
3
PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.肺肉瘤样癌中 PD-L1 和 CD47 的共表达:预后不良的预测因子和未来联合免疫治疗的潜在靶点。
J Cancer Res Clin Oncol. 2019 Dec;145(12):3055-3065. doi: 10.1007/s00432-019-03023-w. Epub 2019 Sep 14.
4
Immunophenotyping of pulmonary sarcomatoid carcinoma.肺肉瘤样癌的免疫表型。
Front Immunol. 2022 Oct 20;13:976739. doi: 10.3389/fimmu.2022.976739. eCollection 2022.
5
Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.PD-L1表达和CD8 + T细胞浸润在肺神经内分泌肿瘤中的预后意义
Diagn Pathol. 2018 May 22;13(1):30. doi: 10.1186/s13000-018-0712-1.
6
Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.肿瘤免疫微环境在肺多形性癌中的预后影响
Lung Cancer. 2021 Mar;153:56-65. doi: 10.1016/j.lungcan.2021.01.007. Epub 2021 Jan 8.
7
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.程序性细胞死亡蛋白1(PD-1)和PD-配体1(PD-L1)在大肠癌细胞及肿瘤浸润淋巴细胞中的表达对结直肠癌的预后影响
Mol Cancer. 2016 Aug 24;15(1):55. doi: 10.1186/s12943-016-0539-x.
8
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.罕见 EGFR 突变型非小细胞肺癌患者的 PD-L1 表达和 T 细胞浸润与免疫治疗反应。
Lung Cancer. 2020 Apr;142:98-105. doi: 10.1016/j.lungcan.2020.02.010. Epub 2020 Feb 19.
9
Galectin-9 in non-small cell lung cancer.半乳糖凝集素-9 在非小细胞肺癌中的作用。
Lung Cancer. 2019 Oct;136:80-85. doi: 10.1016/j.lungcan.2019.08.014. Epub 2019 Aug 16.
10
Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).程序性死亡配体-1和CD8肿瘤浸润淋巴细胞(TILs)作为高级别浆液性卵巢癌(HGSC)的预后预测指标
J Egypt Natl Canc Inst. 2021 Jul 9;33(1):16. doi: 10.1186/s43046-021-00073-5.

引用本文的文献

1
Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy.半乳糖凝集素-9——一种新兴的癌症治疗糖免疫检查点靶点。
Int J Mol Sci. 2025 Aug 19;26(16):7998. doi: 10.3390/ijms26167998.
2
Clinical characteristics and survival outcomes in patients with pulmonary sarcomatoid carcinoma: a multicenter retrospective study.肺肉瘤样癌患者的临床特征与生存结局:一项多中心回顾性研究
Clin Transl Oncol. 2024 Dec 25. doi: 10.1007/s12094-024-03823-8.
3
Blood Microbiota and Its Products: Mechanisms of Interference with Host Cells and Clinical Outcomes.

本文引用的文献

1
Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.基于半乳糖凝集素-9 的免疫风险评分模型有助于预测 I-III 期小细胞肺癌的复发。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001391.
2
Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma.综合分子特征分析揭示了肺肉瘤样癌的潜在治疗策略。
Nat Commun. 2020 Sep 28;11(1):4878. doi: 10.1038/s41467-020-18702-3.
3
Neutrophil diversity and plasticity in tumour progression and therapy.
血液微生物群及其产物:干扰宿主细胞的机制与临床结局
Hematol Rep. 2024 Jul 6;16(3):440-453. doi: 10.3390/hematolrep16030043.
4
Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes.肺肉瘤样癌的综合基因组和转录组分析确定了与不同免疫特征和临床结果相关的分子亚型。
Cancer Innov. 2024 Apr 15;3(3):e112. doi: 10.1002/cai2.112. eCollection 2024 Jun.
5
Prognostic Value of F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma.F-FDG PET/CT 影像组学对结外鼻型 NK/T 细胞淋巴瘤的预后价值
Korean J Radiol. 2024 Feb;25(2):189-198. doi: 10.3348/kjr.2023.0618.
6
Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target.半乳糖凝集素-9在癌症治疗中的作用:从免疫检查点配体到有前景的治疗靶点。
Front Cell Dev Biol. 2024 Jan 9;11:1332205. doi: 10.3389/fcell.2023.1332205. eCollection 2023.
7
Integrated pathological analysis to develop a Gal-9 based immune survival stratification to predict the outcome of lung large cell neuroendocrine carcinoma and its usefulness in immunotherapy.整合病理分析,建立基于 Gal-9 的免疫生存分层,预测肺大细胞神经内分泌癌的预后及其在免疫治疗中的作用。
Int J Biol Sci. 2022 Sep 25;18(15):5913-5927. doi: 10.7150/ijbs.76936. eCollection 2022.
8
Applications of machine learning in tumor-associated macrophages.机器学习在肿瘤相关巨噬细胞中的应用。
Front Immunol. 2022 Sep 23;13:985863. doi: 10.3389/fimmu.2022.985863. eCollection 2022.
9
Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review.使用PD-1抑制剂卡瑞利珠单抗治疗多原发性恶性肿瘤:一例报告及文献综述
Front Oncol. 2022 Jul 5;12:911961. doi: 10.3389/fonc.2022.911961. eCollection 2022.
中性粒细胞的多样性和可塑性在肿瘤进展和治疗中的作用。
Nat Rev Cancer. 2020 Sep;20(9):485-503. doi: 10.1038/s41568-020-0281-y. Epub 2020 Jul 21.
4
Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report.肺肉瘤样癌对纳武利尤单抗联合安罗替尼的显著反应:一例报告
Case Rep Oncol. 2020 Jun 4;13(2):601-605. doi: 10.1159/000507568. eCollection 2020 May-Aug.
5
Characterising the prognostic potential of HLA-DR during colorectal cancer development.分析 HLA-DR 在结直肠癌发展过程中的预后潜力。
Cancer Immunol Immunother. 2020 Aug;69(8):1577-1588. doi: 10.1007/s00262-020-02571-2. Epub 2020 Apr 18.
6
ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy.免疫细胞人工智能(ImmuCellAI):一种用于全面预测T细胞亚群丰度的独特方法及其在癌症免疫治疗中的应用。
Adv Sci (Weinh). 2020 Feb 11;7(7):1902880. doi: 10.1002/advs.201902880. eCollection 2020 Apr.
7
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.免疫检查点抑制剂在肺肉瘤样癌中的疗效。
J Thorac Oncol. 2020 May;15(5):860-866. doi: 10.1016/j.jtho.2020.01.014. Epub 2020 Jan 25.
8
T Cell Reprogramming Against Cancer.T 细胞重编程抗癌。
Methods Mol Biol. 2020;2097:3-44. doi: 10.1007/978-1-0716-0203-4_1.
9
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.非小细胞肺癌中肿瘤浸润淋巴细胞的OX40和OX40L蛋白表达及其在临床结局中的作用以及与其他免疫生物标志物的关系
Transl Lung Cancer Res. 2019 Aug;8(4):352-366. doi: 10.21037/tlcr.2019.08.15.
10
PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.肺肉瘤样癌中 PD-L1 和 CD47 的共表达:预后不良的预测因子和未来联合免疫治疗的潜在靶点。
J Cancer Res Clin Oncol. 2019 Dec;145(12):3055-3065. doi: 10.1007/s00432-019-03023-w. Epub 2019 Sep 14.